ATE183235T1 - Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon - Google Patents

Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon

Info

Publication number
ATE183235T1
ATE183235T1 AT91104432T AT91104432T ATE183235T1 AT E183235 T1 ATE183235 T1 AT E183235T1 AT 91104432 T AT91104432 T AT 91104432T AT 91104432 T AT91104432 T AT 91104432T AT E183235 T1 ATE183235 T1 AT E183235T1
Authority
AT
Austria
Prior art keywords
gag
vaccinia
addition
particles
expression
Prior art date
Application number
AT91104432T
Other languages
English (en)
Inventor
Hans Prof Dr Wolf
Holger Dipl-Biol Fliessbach
Brunn Albrecht Dr V
Ralf Dipl-Biol Wagner
Manfred Dr Motz
Original Assignee
Wolf Hans Joachim Prof Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8203785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE183235(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wolf Hans Joachim Prof Dr filed Critical Wolf Hans Joachim Prof Dr
Application granted granted Critical
Publication of ATE183235T1 publication Critical patent/ATE183235T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT91104432T 1990-03-21 1991-03-21 Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon ATE183235T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90105319 1990-03-21

Publications (1)

Publication Number Publication Date
ATE183235T1 true ATE183235T1 (de) 1999-08-15

Family

ID=8203785

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91104432T ATE183235T1 (de) 1990-03-21 1991-03-21 Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon

Country Status (5)

Country Link
EP (1) EP0449116B2 (de)
AT (1) ATE183235T1 (de)
DE (1) DE69131513T3 (de)
ES (1) ES2140380T5 (de)
GR (1) GR3031817T3 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773211A (en) * 1991-07-10 1998-06-30 Abbott Laboratories Differentiation of HTLV-I and HTLV-II using synthetic peptides
GB9208218D0 (en) * 1992-04-14 1992-05-27 British Bio Technology Hybrid particles
JPH07505412A (ja) * 1992-04-14 1995-06-15 ブリティッシュ　バイオテック　ファーマシューティカルズリミテッド Ｃｔｌ応答の誘導
CA2084386C (en) * 1992-06-04 2001-02-20 Atsushi Saito Hiv antigen
WO1995004147A1 (en) * 1993-08-02 1995-02-09 Chiron Corp Recombinant constructs using replacement sequences in hypervariable regions
ATE288488T1 (de) * 1997-03-11 2005-02-15 Mayo Foundation Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
WO2000039303A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Modified hiv env polypeptides
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1311686A2 (de) * 2000-08-14 2003-05-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Modifikationen der env-, gag- und pol-protein des hiv-virus erhöhen die immunogenwirkung genetischer impfstoffe
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030198621A1 (en) 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
RU2214274C2 (ru) * 2001-08-16 2003-10-20 Государственное предприятие Институт иммунологии Федерального управления медико-биологических экстремальных проблем при МЗ РФ Иммуногенная композиция, содержащая химерный полипептид вич, полипептиды и тест-система для обнаружения антител к вич
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1427806A4 (de) 2001-08-31 2006-04-26 Chiron Corp Antigene hiv-typ-b-polypeptide codierende polynukleotide, polypeptide und verwendungen davon
US6835568B2 (en) 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
EP1814583A2 (de) 2004-11-01 2007-08-08 Novartis Vaccines and Diagnostics, Inc. Kombinationswege zur erzeugung von immunantworten
US8620059B2 (en) 2007-12-13 2013-12-31 Fpinnovations Characterizing wood furnish by edge pixelated imaging
US20140004146A1 (en) * 2011-03-17 2014-01-02 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Method for producing virus-like particle by using drosophila cell and applications thereof
CA2832022C (en) 2011-04-06 2019-01-08 Biovaxim Limited Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
WO2015193143A1 (en) 2014-06-18 2015-12-23 Morphosys Ag Fusion proteins and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
ATE110112T1 (de) * 1988-05-06 1994-09-15 Ferropas Ag Verfahren und systeme zur herstellung von hiv- antigenen.

Also Published As

Publication number Publication date
EP0449116B1 (de) 1999-08-11
EP0449116A1 (de) 1991-10-02
EP0449116B2 (de) 2004-08-25
GR3031817T3 (en) 2000-02-29
DE69131513T2 (de) 2000-05-04
ES2140380T5 (es) 2005-03-16
ES2140380T3 (es) 2000-03-01
DE69131513D1 (de) 1999-09-16
DE69131513T3 (de) 2005-05-25

Similar Documents

Publication Publication Date Title
ATE183235T1 (de) Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon
US5580773A (en) Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
Lipka et al. Segregation of human T cell lymphotropic virus type I and II infections by antibody reactivity to unique viral epitopes
Strand et al. Structural proteins of mammalian oncogenic RNA viruses: immunological characterization of the p15 polypeptide of Rauscher murine virus
US5550052A (en) Hybrid cell line formed between T4 lymphocytes and tumoral lymphoid type cells
JPS62244393A (ja) Ｈｔｌｖ−３ｇａｇ／ｅｎｖ遺伝子蛋白質の発現と精製
AP368A (en) Derivatives of gp160 and vaccine based on gp160 or a derivative thereof, containing an adjuvant.
EP0602046B2 (de) Detektion des immunschwäche-virus aus felis
ATE297984T1 (de) Mit hiv-2 infizierte menschliche t-zelllinie die funktionell intaktes hiv-2 gp160 sekretiert
US5443828A (en) Chimeric HIV-2 gag particles
JP3271666B2 (ja) Ｈｔｌｖ―ｉ、ｈｔｌｖ―ｉｉ又は関連レトロウイルスに対する抗体間の識別、新規ペプチド、抗体の検出及び免疫アッセイキット
Laurent et al. Cell surface expression of several species of human immunodeficiency virus type 1 major core protein
DE3879881D1 (de) Rekombinante hiv-2 polypeptide.
Pauletti et al. Application of a modified computer algorithm in determining potential antigenic determinants associated with the AIDS virus glycoprotein
EP0572737A3 (de) Gag-Env Fusion-Antigen aus HIV.
EP0550485A1 (de) Ein adjuvans enthaltende gp160 derivate, impfstoffe auf gp160- oder derivatbasin
DE3850593T3 (de) Synthetische Antigene zur Bestimmung der AIDS-bezogenen, von LAV-2 verursachten Krankheiten.
Robert-Guroff et al. A monoclonal antibody specific for a 52,000-molecular-weight human T-cell leukemia virus-associated glycoprotein expressed by infected cells
Marin et al. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus
Edouard et al. Characterization of monoclonal antibodies directed against the gp46 of human T-cell leukemia virus type I.
JPS63254983A (ja) エイズの病原であるウイルスのｐ２５蛋白質をコードするウイルスベクター及び組換ＤＮＡ、感染された細胞培養物、得られる蛋白質、ワクチン及び得られる抗体
AR020093A1 (es) Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, oligonucleotido para hibridarse con el acido nucleico
CA2084136A1 (en) Design, construction and expression of chimeric proteins for development of vaccines and diagnostic reagents
JPH01148183A (ja) 組み換えワクチニアウイルス

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 0449116

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee